Disarming cancer’s defenses to improve immunotherapy – FierceBiotech
FierceBiotech |
Disarming cancer’s defenses to improve immunotherapy
FierceBiotech “Using checkpoint blockade has revolutionized the field of cancer immunotherapy, but it is not enough to simply stop the cancer from evading the immune system, we need to boost the immune system to fight the cancer off. By combining checkpoint blockade … |
|
Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits
Genetic Engineering & Biotechnology News Solid Biosciences restated its commitment to developing its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, despite the FDA’s full and partial clinical holds on a Phase I/II trial for the treatment. The FDA last month … |
|
Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits
Genetic Engineering & Biotechnology News Solid Biosciences restated its commitment to developing its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, despite the FDA’s full and partial clinical holds on a Phase I/II trial for the treatment. The FDA last month … |